Time between combination therapies approval and patient access in Europe 2023
This statistic displays the average time between an combination therapies gaining marketing authorization and patient access in European countries as of January 1, 2023. According to the data, Switzerland had an average time of 94 days between authorization and patient access for combination therapies (for therapies launchend from 2018 to 2021), compared to 768 days in Romania.